Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
2024 · Nature · 280 citations
https://doi.org/10.1038/s41586-024-07205-6
Y
Yingyun Wang
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
109
Papers
1.3K
Citations
13
h-index
14
i10-index
Yingyun Wang is an academic researcher from Zhengzhou University. The author has contributed to research in topics: Cancer, Hypoxia, and Metabolism & Cancer Research and Treatments & ATP Synthase and ATPases Research. The author has an h-index of 13, co-authored 93 publications.
ORCID: 0009-0006-6917-0245Papers by this author
worksTranslational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2024 · Cancer Discovery · 241 citations
https://doi.org/10.1158/2159-8290.cd-24-0027
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
2024 · Nature · 157 citations
https://doi.org/10.1038/s41586-024-07379-z
Discovery of Daraxonrasib (RMC-6236), a Potent and Orally Bioavailable RAS(ON) Multi-selective, Noncovalent Tri-complex Inhibitor for the Treatment of Patients with Multiple RAS-Addicted Cancers
2025 · Journal of Medicinal Chemistry · 37 citations
https://doi.org/10.1021/acs.jmedchem.4c02314
Supplementary Table S8 from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2024 · 0 citations
https://doi.org/10.1158/2159-8290.25956755.v1
Supplementary Method from Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
2024 · 0 citations
https://doi.org/10.1158/2159-8290.25956779.v1
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat